Wikidata

(Q54470922)

English

Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.

scientific article

In more languages
default for all languages
No label defined

No description defined

Statements

title
Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial (English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
23161899
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23161899%20AND%20SRC:MED&resulttype=core&format=json
retrieved
18 February 2020
author name string

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q54470922&oldid=1260506770"